




Simple Platform for Complex Biology



### Products | OrganoPlatform

- ▶ IFlowPlate384
- ▶ AngioPlate384
- ▶ UniPlate384
- ▶ UniPlate384 II


### Products | Supporting Equipment

- ▶ IFlowRocker (Uni-&bi-directional perfusion)
- ▶ AngioTEER (Tissue barrier monitoring)
- ▶ AeroLung (Aerosol delivery)

### Services | OrganoAssays



- ▶ Cancer model for immune-oncology
- ▶ Blood brain barrier and vascular disease
- ▶ Colon model for inflammatory bowel disease
- ▶ Airway model for Asthma and viral infection
- ▶ Alveoli model for pulmonary fibrosis
- ▶ Kidney model for renal fibrosis and toxicity screening
- ▶ Placenta model for maternal-to-fetus drug transport

**Available readouts** | Single cell seq (Parse), flow cytometry, histology, SEM, TEM, cytokines analysis, Immunostaining, ELISA, TEER, dextran permeability assay, fluorescent-based live cell tracking under dynamic perfusion, collagen assay, mass spectrometry.



**ORGANOBIOTECH** offers high-throughput, automation compatible platforms for 3D tissue and organoid culture. By integrating 3D printing directly into multi-well plates, the platform combines tissue complexity with scalable experimentation. Its open-well design supports standard pipetting workflows, works seamlessly with automation systems, and feels familiar to anyone experienced with conventional multi-well plates. In addition to our products, we offer OrganoAssay services, supporting customers with assay development, disease modeling, screening studies, and custom preclinical projects using advanced 3D tissue and organoid systems.

**USE CASE** | Collaboration with Merck demonstrates integration of the platform into large pharma workflows. Performance is preserved in industrial automated blood vessel model production on AngioPlate - protocols translate directly from OrganoLab to pharma environment.



Left: fluorescence image showing vascular networks in a single plate run  
 Right: permeability assay data. 4 kDa dextran CV: 17.5% (Merck) vs 17.4% (OrganoLab); 65 kDa dextran CV: 29.0% (Merck) vs 29.1% (OrganoLab). Lin, et al. Advanced Healthcare Materials, 2026; study in collaboration with Merck 3D Technologies

### FEATURED PARTNERSHIP AND CLIENTS






www.organo-biotech.com

info@organo-biotech.com

Blood vessels



Airway

Alveoli






Tumor

Kidney



Colon

Placenta



**OrganoAssay**

**ENGAGEMENT OPTIONS**

**RECOMMENDED FOR ACADEMIA**

**RECOMMENDED FOR INDUSTRY**

**DISCOVER**  
*Familiarization and technology validation*

**ENABLE**  
*Client-led assay development*

**DEVELOP**  
*OrganoBiotech-led assay development/delivery*

**PARTNER**  
*OrganoBiotech-led dataset generation*

**TIMELINE**      One-time      6 months      1 year      Continuous

**SUPPORT**      10h\* + standard SOP      10h/month\* + full SOP library      Customized protocol development + training      Full project management

**DELIVERABLES**      4 plates + IFlowRocker      15 plates + IFlowRocker + AngioTEER      15 plates + IFlowRocker + AngioTEER + Protocol transfer      Dataset transfer



**OrganoLab**



*\*virtual engagement*